Our top pick for
AVROBIO, Inc is a biotechnology business based in the US. AVROBIO shares (AVRO) are listed on the NASDAQ and all prices are listed in US Dollars. AVROBIO employs 121 staff and has a market cap (total outstanding shares value) of USD$571.4 million.
Since the stock market crash in March caused by coronavirus, AVROBIO's share price has had significant negative movement.
Its last market close was USD$16.22, which is 28.70% down on its pre-crash value of USD$22.75 and 66.19% up on the lowest point reached during the March crash when the shares fell as low as USD$9.76.
If you had bought USD$1,000 worth of AVROBIO shares at the start of February 2020, those shares would have been worth USD$712.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$803.38.
|Latest market close||USD$16.22|
|52-week range||USD$9.76 - USD$28.44|
|50-day moving average||USD$15.1044|
|200-day moving average||USD$16.7925|
|Wall St. target price||USD$37.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.536|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||-0.86%|
|1 month (2020-10-23)||-2.76%|
|3 months (2020-08-25)||-4.53%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-25)||1.19%|
|2 years (2018-11-23)||-34.46%|
|3 years (2017-11-23)||N/A|
|5 years (2015-11-23)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-33.89%|
|Return on equity TTM||-56.92%|
|Market capitalisation||USD$571.4 million|
TTM: trailing 12 months
There are currently 3.2 million AVROBIO shares held short by investors – that's known as AVROBIO's "short interest". This figure is 14.4% up from 2.8 million last month.
There are a few different ways that this level of interest in shorting AVROBIO shares can be evaluated.
AVROBIO's "short interest ratio" (SIR) is the quantity of AVROBIO shares currently shorted divided by the average quantity of AVROBIO shares traded daily (recently around 196181.74019608). AVROBIO's SIR currently stands at 16.32. In other words for every 100,000 AVROBIO shares traded daily on the market, roughly 16320 shares are currently held short.
However AVROBIO's short interest can also be evaluated against the total number of AVROBIO shares, or, against the total number of tradable AVROBIO shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVROBIO's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 AVROBIO shares in existence, roughly 90 shares are currently held short) or 0.1033% of the tradable shares (for every 100,000 tradable AVROBIO shares, roughly 103 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AVROBIO.
Find out more about how you can short AVROBIO stock.
We're not expecting AVROBIO to pay a dividend over the next 12 months.
Over the last 12 months, AVROBIO's shares have ranged in value from as little as $9.76 up to $28.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVROBIO's is 1.6847. This would suggest that AVROBIO's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.